Glaukos Corporation GKOS

GKOS Company Overview

Glaukos Corporation (NYSE: GKOS) is a U.S.-based ophthalmic medical technology company focused on developing and commercializing therapies for glaucoma, corneal disorders, and retinal diseases. The company operates primarily in the ophthalmology and medical device industries, with a strategic emphasis on minimally invasive and interventional treatments designed to address chronic eye diseases. Its core revenue drivers include implantable glaucoma devices, pharmaceutical therapies, and surgical technologies used by ophthalmologists and ambulatory surgical centers.

The company is best known for pioneering the micro-invasive glaucoma surgery (MIGS) category through its iStent technologies. Over time, Glaukos expanded beyond glaucoma into corneal health and retinal drug delivery through internal development and acquisitions. The company was founded in 1998 and has evolved from a single-product glaucoma device developer into a diversified ophthalmic platform company with commercial operations across multiple therapeutic categories. Public disclosures in SEC filings and company investor materials consistently identify innovation in interventional ophthalmology as a central strategic differentiator.